189 related articles for article (PubMed ID: 30570691)
1. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.
Preskorn SH
Handb Exp Pharmacol; 2019; 250():307-324. PubMed ID: 30570691
[TBL] [Abstract][Full Text] [Related]
2. Drug Development in Psychiatry: The Long and Winding Road from Chance Discovery to Rational Development.
Preskorn SH
Adv Neurobiol; 2023; 30():1-18. PubMed ID: 36928844
[TBL] [Abstract][Full Text] [Related]
3. Rapid-acting antidepressants.
Witkin JM; Martin AE; Golani LK; Xu NZ; Smith JL
Adv Pharmacol; 2019; 86():47-96. PubMed ID: 31378256
[TBL] [Abstract][Full Text] [Related]
4. What is the mechanism of Ketamine's rapid-onset antidepressant effect? A concise overview of the surprisingly large number of possibilities.
Strasburger SE; Bhimani PM; Kaabe JH; Krysiak JT; Nanchanatt DL; Nguyen TN; Pough KA; Prince TA; Ramsey NS; Savsani KH; Scandlen L; Cavaretta MJ; Raffa RB
J Clin Pharm Ther; 2017 Apr; 42(2):147-154. PubMed ID: 28111761
[TBL] [Abstract][Full Text] [Related]
5. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent.
Preskorn S; Macaluso M; Mehra DO; Zammit G; Moskal JR; Burch RM;
J Psychiatr Pract; 2015 Mar; 21(2):140-9. PubMed ID: 25782764
[TBL] [Abstract][Full Text] [Related]
6. Current perspectives on the development of non-biogenic amine-based antidepressants.
Skolnick P; Legutko B; Li X; Bymaster FP
Pharmacol Res; 2001 May; 43(5):411-23. PubMed ID: 11394932
[TBL] [Abstract][Full Text] [Related]
7. Glutamate-based antidepressants: 20 years on.
Skolnick P; Popik P; Trullas R
Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
[TBL] [Abstract][Full Text] [Related]
8. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Hashimoto K
Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression.
Vecera CM; C Courtes A; Jones G; Soares JC; Machado-Vieira R
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004437
[TBL] [Abstract][Full Text] [Related]
10. Drug-Drug Interactions (DDIs) in Psychiatric Practice, Part 8: Relative Receptor Binding Affinity as a Way of Understanding the Differential Pharmacology of Currently Available Antidepressants.
Preskorn SH
J Psychiatr Pract; 2020 Jan; 26(1):46-51. PubMed ID: 31913969
[TBL] [Abstract][Full Text] [Related]
11. Glutamate-Based Drug Discovery for Novel Antidepressants.
Pałucha-Poniewiera A; Pilc A
Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
[TBL] [Abstract][Full Text] [Related]
12. [Research progress of depression and the application of esketamine].
Lin FB; Hou DR; Tang QP
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Apr; 37(4):567-inside back cover. PubMed ID: 28446416
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.
Molero P; Ramos-Quiroga JA; Martin-Santos R; Calvo-Sánchez E; Gutiérrez-Rojas L; Meana JJ
CNS Drugs; 2018 May; 32(5):411-420. PubMed ID: 29736744
[TBL] [Abstract][Full Text] [Related]
14. Investigational NMDA receptor modulators for depression.
Szewczyk B; Pałucha-Poniewiera A; Poleszak E; Pilc A; Nowak G
Expert Opin Investig Drugs; 2012 Jan; 21(1):91-102. PubMed ID: 22097925
[TBL] [Abstract][Full Text] [Related]
15. Subtypes of Major Depressive Disorder Based on Pharmacological Responsiveness.
Preskorn SH
J Psychiatr Pract; 2021 Nov; 27(6):448-452. PubMed ID: 34768267
[TBL] [Abstract][Full Text] [Related]
16. A brief history of antidepressant drug development: from tricyclics to beyond ketamine.
Pereira VS; Hiroaki-Sato VA
Acta Neuropsychiatr; 2018 Dec; 30(6):307-322. PubMed ID: 29388517
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomics, informatics, and individual drug therapy in psychiatry: past, present and future.
Preskorn SH
J Psychopharmacol; 2006 Jul; 20(4 Suppl):85-94. PubMed ID: 16785276
[TBL] [Abstract][Full Text] [Related]
18. Human induced pluripotent stem cells technology in treatment resistant depression: novel strategies and opportunities to unravel ketamine's fast-acting antidepressant mechanisms.
Marcatili M; Sala C; Dakanalis A; Colmegna F; D'Agostino A; Gambini O; Dell'Osso B; Benatti B; Conti L; Clerici M
Ther Adv Psychopharmacol; 2020; 10():2045125320968331. PubMed ID: 33224469
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant actions of ketamine: from molecular mechanisms to clinical practice.
Monteggia LM; Zarate C
Curr Opin Neurobiol; 2015 Feb; 30():139-43. PubMed ID: 25562451
[TBL] [Abstract][Full Text] [Related]
20. Targeting glutamate signalling in depression: progress and prospects.
Murrough JW; Abdallah CG; Mathew SJ
Nat Rev Drug Discov; 2017 Jul; 16(7):472-486. PubMed ID: 28303025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
